Treatment-related mortality in newly diagnosed pediatric cancer: a population-based analysis

Cancer Medicine
Paul GibsonInternational Pediatric Oncology Mortality Classification (IPOMC) Group

Abstract

Using a previously developed reliable and valid treatment-related mortality (TRM) definition, our objective was to describe the proportion of children newly diagnosed with cancer experiencing TRM and to identify risk factors for TRM in a population-based cohort. We included children with cancer <19 years diagnosed and treated in Ontario who were diagnosed between 2003 and 2012. Children with cancer were identified using data in a provincial registry. Cumulative incidence of TRM was calculated where progressive disease death was considered a competing event. Among the 5179 children included, 179 had TRM, 478 died of progressive disease, and 4522 were still alive. At 5 years, the cumulative incidence of TRM among the entire cohort was 3.9% (95% confidence interval (CI) 3.3-4.5%). When compared to brain tumor patients, leukemia and lymphoma patients had a significantly higher risk of TRM (hazard ratio (HR) 2.5, 95% CI: 1.6-4.0; P < 0.0001). Infants were at significantly higher risk of TRM across diagnostic groups. Other factors associated with higher risks of TRM were metastatic disease (P < 0.0001), diagnosis prior to 1 January 2008 (P = 0.001), hematopoietic stem cell transplantation (HSCT) (P < 0.0001), and relapse (P < 0.0001)...Continue Reading

References

Jun 1, 2000·Acta Paediatrica·A W Craft
Apr 3, 2003·International Journal of Cancer. Journal International Du Cancer·Mark L GreenbergCorin Greenberg
Jun 14, 2005·Epidemiology·Marilyn J BorugianMary L McBride
Feb 9, 2011·BMJ : British Medical Journal·Ian R WhiteStuart J Pocock
Feb 4, 2014·CA: a Cancer Journal for Clinicians·Elizabeth WardAhmedin Jemal
Dec 19, 2015·The Lancet Oncology·Sarah AlexanderUNKNOWN International Pediatric Oncology Mortality Classification Group

❮ Previous
Next ❯

Software Mentioned

POGONIS
SAS PC
SAS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.